World Pharma News Digest - 10.02.2014
8 views
Skip to first unread message
Ruslan David
Feb 10, 2014, 5:26:39 AM2/10/14
to worldph...@googlegroups.com
New drug candidates from genome sequence
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
Read more...
http://www.worldpharmanews.com/research/2697-new-drug-candidates-from-genome-sequence
Scientists create potential vaccine ingredient for childhood respiratory disease
Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality. The virus has been resistant to current vaccine-design strategies.
Read more...
http://www.worldpharmanews.com/research/2696-scientists-create-potential-vaccine-ingredient-for-childhood-respiratory-disease
Pfizer and Merck to collaborate on innovative anti-cancer combination studies
Pfizer Inc. (NYSE:PFE) has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer's axitinib (INLYTA®) in renal cell carcinoma (RCC).
Read more...
http://www.worldpharmanews.com/pfizer/2695-pfizer-and-merck-to-collaborate-on-innovative-anti-cancer-combination-studies
Electronically controlled drugs could minimize side effects
Potential side effects of many of today's therapeutic drugs can be downright frightening - just listen carefully to a drug commercial on TV. These effects often occur when a drug is active throughout the body, not just where and when it is needed. But scientists are reporting progress on a new tailored approach to deliver medicine in a much more targeted way. The study on these new electronically controlled drugs appears in the journal ACS Nano.
Read more...
http://www.worldpharmanews.com/research/2694-electronically-controlled-drugs-could-minimize-side-effects
Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma
Amgen (NASDAQ:AMGN) and Merck, known as MSD outside the United States and Canada, announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma.
Read more...
http://www.worldpharmanews.com/amgen/2693-amgen-and-merck-announce-collaboration-to-evaluate-investigational-combination-treatment-for-advanced-melanoma
Existing medicines show promise for treating stomach and bowel cancer
Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered. The finding, in preclinical models, that medicines called 'JAK inhibitors' reduce the growth of inflammation-associated stomach and bowel cancer provides the first evidence supporting their use in treating these cancers.
Read more...
http://www.worldpharmanews.com/research/2692-existing-medicines-show-promise-for-treating-stomach-and-bowel-cancer
Experts issue 'blueprint for action' to combat shortages of life-saving drugs
A group of prominent healthcare experts including bioethicists, pharmacists, policymakers and cancer specialists have proposed concrete steps for preventing and managing a nightmare scenario that is becoming all too common: shortages of life-saving drugs. In a consensus statement published in the journal Pediatrics, the experts say they sought to move away from the current strategy of reaction to shortages once they have occurred and focus instead on prevention.
Read more...
http://www.worldpharmanews.com/research/2691-experts-issue-blueprint-for-action-to-combat-shortages-of-life-saving-drugs
Bristol-Myers Squibb completes previously announced sale of global diabetes business to AstraZeneca
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced sale of its global diabetes business to AstraZeneca. Bristol-Myers Squibb received from AstraZeneca a payment of approximately $2.7 billion in connection with the closing, and will receive by mid-February, a $0.6 billion milestone payment from the recent U.S. approval of Farxiga (dapagliflozin).
Read more...
http://www.worldpharmanews.com/bms/2690-bristol-myers-squibb-completes-previously-announced-sale-of-global-diabetes-business-to-astrazeneca
PharmaNews.eu / Latest News
Researchers at UGent and VIB, discovered potential novel treatment against septic shock
http://www.pharmanews.eu/research-and-development/1398-researchers-at-ugent-and-vib-discovered-potential-novel-treatment-against-septic-shock
Study reveals record rise in insulin use
http://www.pharmanews.eu/research-and-development/1399-study-reveals-record-rise-in-insulin-use
New drug treatment reduces chronic pain following shingles
http://www.pharmanews.eu/research-and-development/1400-new-drug-treatment-reduces-chronic-pain-following-shingles
Committee for orphan medicines - overview of 2013 and looking ahead
http://www.pharmanews.eu/ema/1397-committee-for-orphan-medicines-overview-of-2013-and-looking-ahead
How an immune molecule makes cancer cells starve
http://www.pharmanews.eu/research-and-development/1396-how-an-immune-molecule-makes-cancer-cells-starve
Major EU research grant focused on stem cell-based treatment of Diabetes
http://www.pharmanews.eu/research-and-development/1395-major-eu-research-grant-focused-on-stem-cell-based-treatment-of-diabetes
Cracks in the cellular transport system can be key to a new generation of cancer therapies
http://www.pharmanews.eu/research-and-development/1394-cracks-in-the-cellular-transport-system-can-be-key-to-a-new-generation-of-cancer-therapies
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
Read more...
http://www.worldpharmanews.com/research/2697-new-drug-candidates-from-genome-sequence
Scientists create potential vaccine ingredient for childhood respiratory disease
Scientists at The Scripps Research Institute (TSRI) have invented a new method for designing artificial proteins, and have used it to make key ingredients for a candidate vaccine against a dangerous virus, respiratory syncytial virus (RSV), a significant cause of infant mortality. The virus has been resistant to current vaccine-design strategies.
Read more...
http://www.worldpharmanews.com/research/2696-scientists-create-potential-vaccine-ingredient-for-childhood-respiratory-disease
Pfizer and Merck to collaborate on innovative anti-cancer combination studies
Pfizer Inc. (NYSE:PFE) has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer's axitinib (INLYTA®) in renal cell carcinoma (RCC).
Read more...
http://www.worldpharmanews.com/pfizer/2695-pfizer-and-merck-to-collaborate-on-innovative-anti-cancer-combination-studies
Electronically controlled drugs could minimize side effects
Potential side effects of many of today's therapeutic drugs can be downright frightening - just listen carefully to a drug commercial on TV. These effects often occur when a drug is active throughout the body, not just where and when it is needed. But scientists are reporting progress on a new tailored approach to deliver medicine in a much more targeted way. The study on these new electronically controlled drugs appears in the journal ACS Nano.
Read more...
http://www.worldpharmanews.com/research/2694-electronically-controlled-drugs-could-minimize-side-effects
Amgen and Merck announce collaboration To evaluate investigational combination treatment for advanced melanoma
Amgen (NASDAQ:AMGN) and Merck, known as MSD outside the United States and Canada, announced today that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec, an investigational oncolytic immunotherapy, combined with MK-3475, an investigational anti-PD-1 immunotherapy, in a Phase 1b/2 study of patients with mid- to late-stage melanoma.
Read more...
http://www.worldpharmanews.com/amgen/2693-amgen-and-merck-announce-collaboration-to-evaluate-investigational-combination-treatment-for-advanced-melanoma
Existing medicines show promise for treating stomach and bowel cancer
Stomach and bowel cancer, two of the most common cancers worldwide, could be treated with a class of medicines that are currently used to treat a blood disorder, a Melbourne research team has discovered. The finding, in preclinical models, that medicines called 'JAK inhibitors' reduce the growth of inflammation-associated stomach and bowel cancer provides the first evidence supporting their use in treating these cancers.
Read more...
http://www.worldpharmanews.com/research/2692-existing-medicines-show-promise-for-treating-stomach-and-bowel-cancer
Experts issue 'blueprint for action' to combat shortages of life-saving drugs
A group of prominent healthcare experts including bioethicists, pharmacists, policymakers and cancer specialists have proposed concrete steps for preventing and managing a nightmare scenario that is becoming all too common: shortages of life-saving drugs. In a consensus statement published in the journal Pediatrics, the experts say they sought to move away from the current strategy of reaction to shortages once they have occurred and focus instead on prevention.
Read more...
http://www.worldpharmanews.com/research/2691-experts-issue-blueprint-for-action-to-combat-shortages-of-life-saving-drugs
Bristol-Myers Squibb completes previously announced sale of global diabetes business to AstraZeneca
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced sale of its global diabetes business to AstraZeneca. Bristol-Myers Squibb received from AstraZeneca a payment of approximately $2.7 billion in connection with the closing, and will receive by mid-February, a $0.6 billion milestone payment from the recent U.S. approval of Farxiga (dapagliflozin).
Read more...
http://www.worldpharmanews.com/bms/2690-bristol-myers-squibb-completes-previously-announced-sale-of-global-diabetes-business-to-astrazeneca
PharmaNews.eu / Latest News
Researchers at UGent and VIB, discovered potential novel treatment against septic shock
http://www.pharmanews.eu/research-and-development/1398-researchers-at-ugent-and-vib-discovered-potential-novel-treatment-against-septic-shock
Study reveals record rise in insulin use
http://www.pharmanews.eu/research-and-development/1399-study-reveals-record-rise-in-insulin-use
New drug treatment reduces chronic pain following shingles
http://www.pharmanews.eu/research-and-development/1400-new-drug-treatment-reduces-chronic-pain-following-shingles
Committee for orphan medicines - overview of 2013 and looking ahead
http://www.pharmanews.eu/ema/1397-committee-for-orphan-medicines-overview-of-2013-and-looking-ahead
How an immune molecule makes cancer cells starve
http://www.pharmanews.eu/research-and-development/1396-how-an-immune-molecule-makes-cancer-cells-starve
Major EU research grant focused on stem cell-based treatment of Diabetes
http://www.pharmanews.eu/research-and-development/1395-major-eu-research-grant-focused-on-stem-cell-based-treatment-of-diabetes
Cracks in the cellular transport system can be key to a new generation of cancer therapies
http://www.pharmanews.eu/research-and-development/1394-cracks-in-the-cellular-transport-system-can-be-key-to-a-new-generation-of-cancer-therapies
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany
eHealthNews.eu, http://www.ehealthnews.eu
eHealthServer.com, http://www.ehealthserver.com
eHealthServer.de, http://www.ehealthserver.de
World Pharma News, http://www.worldpharmanews.com
PharmaNews.eu, http://www.pharmanews.eu
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please download World Pharma News' Media Pack: http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages